Fenofibric
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 312 publications
Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components.
Journal: Clinical pharmacology in drug development
Published: December 01, 2025
Determination of fenofibric acid in saliva and exhaled breath condensate samples using metal- organic frameworks based dispersive micro solid phase extraction coupled to HPLC-PDA.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: October 04, 2025
Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: August 04, 2025
Antiepileptic drugs and lipid-lowering agents in surface water in Colombia: occurrence, ecological threat, and removal strategies.
Journal: Environmental science and pollution research international
Published: June 02, 2025
Mitochondrial-Targeted Multifunctional Platinum-Based Nano "Terminal-Sensitive Projectile" for Enhanced Cancer Chemotherapy Efficacy.
Journal: ACS nano
Published: February 25, 2025
A facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate.
Journal: Results in chemistry
Published: August 01, 2024
Administration time modify the anxiolytic and antidepressant effects of inulin via gut-brain axis.
Journal: International journal of biological macromolecules
Published: July 26, 2024
Significantly improving the solubility and anti-inflammatory activity of fenofibric acid with native and methyl-substituted beta-cyclodextrins via complexation.
Journal: Scientific reports
Published: July 24, 2024
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease.
Journal: Journal of clinical pharmacology
Published: June 27, 2024
Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease.
Journal: Biomedicines
Published: February 13, 2024
Last Updated: 04/28/2026